They differ in origin, proposed mechanism and the depth of the human record. TB-500 is based on thymosin beta-4, a 43-amino-acid protein found inside nearly all human cells. Its proposed action runs through actin, the protein cells use to move toward an injury (PMID 1999398, PMID 10469335). BPC-157 is a 15-amino-acid peptide derived from a gastric protein fragment (PMID 42198317). Its preclinical work centers on blood-vessel recruitment and the lining of the gut (PMID 29879879).
The human evidence differs too. Thymosin beta-4 has randomized Phase II trials, all in eye-drop or topical forms (PMID 26056426, PMID 17495250). BPC-157 has no randomized human trial in the record. A 2025 systematic review in orthopaedic sports medicine describes its musculoskeletal promise as resting on preclinical studies (PMID 40756949).
The regulatory record is the same for both. Neither is FDA-approved or on FDA’s 503A Bulks List. FDA removed both from its Category 2 list in April 2026, and on July 23, 2026, FDA’s Pharmacy Compounding Advisory Committee voted to recommend both. FDA has not acted on that vote, though since October 30, 2026 an HHS policy lets a licensed 503A pharmacy compound TB-500 on a prescription. The table above sets the two side by side.